CAR T Cell therapy, CAR T cells, CAR T Therapy, DLBCL
Efficacy of CAR T Cell Therapy in B-Cell lymphoma Richter Transformation
What is the Richter transformation? Richter transformation is an infrequent but not rare occurrence when an aggressive B-cell lymphoma develops in people with chronic lymphocytic leukemia or small lymphocytic lymphoma. The progno..
CD20, Columvi, DLBCL, Genentech
Glofitamab-gxbm is approved by FDA for selected relapsed or refractory large B-cell lymphomas
July 2023: The Food and Drug Administration gave accelerated approval to glofitamab-gxbm (Columvi, Genentech, Inc.) for relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS) or large B-cell ly..
B-cell lymphoma, DLBCL, POLARIX, Polatuzumab, polatuzumab vedotin
Polatuzumab vedotin-piiq is approved by USFDA for previously untreated diffuse large B-cell lymphoma, not otherwise specified, and high-grade B-cell lymphoma
May 2023: For adult patients with high-grade B-cell lymphoma (HGBL), not otherwise specified (NOS), or diffuse large B-cell lymphoma (DLBCL) who have not previously received treatment and who have an International Prognostic Inde..
CAR - T Cell therapy, CARsgen Therapeutics Co, Daiichi Sankyo Company, DLBCL, Emergen Research, Limited, Novartis AG
CAR T-Cell therapy market will grow at phenomenal rate in next 8 years
July 2022: According to the most recent research conducted by Emergen Research, the global market for CAR T-cells therapy reached a size of USD 1.29 billion in 2021 and is expected to register a revenue CAGR of 24.9 percent ..
Burkitt lymphoma, Burkitt-like lymphoma, DLBCL, Genentech, Rituxan, Rituximab
Rituximab plus chemotherapy is approved by FDA for pediatric cancer indications
March 2022: The Food and Drug Administration has approved rituximab (Rituxan, Genentech, Inc.) in conjunction with chemotherapy for CD20-positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma..
ADC Therapeutics SA, alkylating agent conjugate, CD19-directed antibody, diffuse large B-cell lymphoma, DLBCL, high-grade B-cell lymphoma, Large B-cell lymphoma, Loncastuximab tesirine-lpyl, Zynlonta
The FDA has granted loncastuximab tesirine-lpyl accelerated approval for large B-cell lymphoma
August 2021: The FDA granted loncastuximab tesirine-lpyl (Zynlonta, ADC Therapeutics SA), a CD19-directed antibody and alkylating agent conjugate, accelerated approval for adult patients with relapsed or refractory large B-cell ly..
DLBCL, Hodgkin lymphoma, lymphoma, NHL, Non Hodgkin lymphoma
Why do young people have a high incidence of lymphoma?
LymphPeople have very little knowledge of lymph. The neck, groin, and armpits are all lymph. If there is a problem with the lymphatic system, the body's toxins will be stored in the body in large quantities, and lymphoma will soon..